Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group.

Autor: Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy., Conteduca V; Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy., Verzoni E; SSD Genitourinary Medical Oncology and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Procopio G; SSD Genitourinary Medical Oncology and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy. Electronic address: ugo.degiorgi@irst.emr.it.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2024 Oct 22; Vol. 204, pp. 104534. Date of Electronic Publication: 2024 Oct 22.
DOI: 10.1016/j.critrevonc.2024.104534
Abstrakt: The definition of "non-metastatic hormone-sensitive prostate cancer" (nmHSPC) can be applied to patients with prostate cancer (PC) who are androgen-deprivation therapy-naïve and without evidence of metastatic disease. This definition includes heterogeneous situations; however, PC patients at high risk of metastatic spread - and who have not started a hormonal treatment - constitute a unique category with unmet clinical needs. This narrative review critically discusses the advances that characterize the rapidly evolving diagnostic and therapeutic scenario in the nmHSPC setting. We found that nmHSPC represents a grey zone in the context of PC. New clinical trials are trying to redefine the therapeutic algorithm of these patients, but escalating treatment seems not to be the right choice for the overall population. Biomarkers able to stratify patients - including molecular ones - are urgently needed, and biomarker-based clinical trials could clarify their prognostic and predictive role in the nmHSPC scenario.
Competing Interests: Declaration of Competing Interest Emilio Francesco Giunta received personal fees from Novartis and travel accommodation from Janssen and Bayer. Giandomenico Roviello received honoraria for advisory boards or invited speaker fees from BMS, Astellas, Bayer, Ipsen, Novartis, Roche, and AstraZeneca. Vincenza Conteduca: received honoraria for advisory boards or speaker fees from Janssen, Astellas, Merck, AstraZeneca, 'Ipsen, Bayer, Novartis, Recordati, BMS, MSD, GSK. Elena Verzoni received honoraria for advisory boards or speaker fees from MSD, Pfizer, Astellas, BMS, AstraZeneca, Ipsen and Janssen. Giuseppe Procopio services advisory boards/consulting for Astellas, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Brystol Myers, BMS, Janssen, EISAI, Ely Lilly, Janssen, IPSEN, Menarini, Merk, MSD, Novartis, Roche, Pfizer. Ugo De Giorgi received honoraria for advisory boards or speaker fees for Pfzer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: